News flow potential short to mid term (2022) share price catalyst. Not in order.
FDA Fast Track to phase 2 human trials CTAP.
Non Equity funding arrangement. (Likely Trading Halt)
Small Trial 1 (5 day course BIT225) outside US in Large Covid Population.
Large FDA trial in US possible 30 cohort (8kg BIT225)
FDA approval 9-12months
Buyout possible anytime.
HIV current studies Immune response combined with ART mid 2022.
Current SP 9c
chart daily, page-2386
-
- There are more pages in this discussion • 908 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
